Why the stagnation in effective therapy for MDS?

Abstract The question posed above assumes that we are going nowhere in therapies for myelodysplastic syndromes (MDS) and asks, why? Yet, in recent years novel and effective therapies for MDS indeed have begun to emerge, particularly in patients with lower-risk disease. Beyond this, however, most of...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Best practice & research. Clinical haematology 2016-12, Vol.29 (4), p.334-340
1. Verfasser:	Blum, William, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Allografts Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation Humans MDS Myelodysplastic syndromes Myelodysplastic Syndromes - therapy Risk Factors Therapy Transplant Trial design
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!